Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intercalated Erlotinib vs Erlotinib in EGFR+ NSCLC
NCT02001896Phase 3Unknown
- Sponsor
- Xinjiang Medical University
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Xinjiang Medical University. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02001896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02001896.